血脂异常治疗策略—争议与进展

Treatment for lipid disorders-controversy and progress

2013年以来，美国、欧洲及中国相继更新了血脂异常管理指南。不同指南所推荐的风险评估工具均有所区别。治疗靶标及强化降脂是否安全亦存在争议。尽管综合措施有所不同，但他汀类作为调脂治疗的基石以降低心血管事件风险仍是各大指南的共识。

Since 2013, guidelines for the management of lipid disorders have been updated in the United States, Europe, and China. Different risk assessment tools are recommended by different guidelines. And there is controversy among guidelines with regard to treatment targets, and whether aggressive lowering of LDL is safe. Despite the differences in overall approaches, the use of statin therapy is the backbone of treatment to reduce risk of cardiovascular events in all guidelines.